argenx is a global immunology company focused on improving the lives for people with rare autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx is translating immunology breakthroughs into therapies for multiple autoimmune diseases including Thyroid Eye Disease.

CONTACT INFORMATION
Shelley Gerson
M.Ed, Associate Director US Patient Advocacy argenx
Thyroid Eye and Graves’ Disease advocacy lead
248-703-3434 cell
sgerson@argenx.com

VISIT OUR WEBSITE
www.argenx.com

CLINICAL STUDIES
UplighTED Thyroid Eye Disease – UplighTED is a Phase 3 Study to Evaluate the Safety and Efficacy of Self-administered efgartigimod SC injection for Adults with Thyroid Eye Disease (TED) – argenx patient study website

HCP Page – UplighTED Thyroid Eye Disease – argenx Healthcare Professionals study website (US)

HCP Homepage — UplighTED – argenx Healthcare Professionals study website (EU)

Poster Print PDF